Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.

Addressing The Unmet Need of Ocular Pain

EyeCool Therapeutics is committed to delivering fast, lasting relief for patients suffering from Chronic Ocular Surface Pain (COSP)

Our Focus

COSP is a newly defined, often misdiagnosed condition marked by persistent eye pain, burning, dryness, and discomfort—even when no clinical signs are visible. First described as a distinct disease state by Galor et al. in 2022, COSP has been shown to be as disabling as fibromyalgia or migraine, yet no FDA-approved treatments exist.1